BioNTech SE
BNTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001776985
In the last 90 days, BioNTech SE insiders filed 0 open-market purchases and 8 sales; 283 institutions reported holding it in 13F filings for Q2 2026, worth $4.36B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $51.2M in total
- 8
- 13F holdersQ2 2026, +11 vs. previous quarter
- 283
- 13F valueReported value at the end of Q2 2026
- $4.36B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding BNTX, Q2 2026
1 superinvestor reports holding BioNTech SE on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by BioNTech SE insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)4:26 PM ET | Sep 23-24 | 1 day | Sahin UgurChief Executive Officer | SSale | −69.0K | $99.17 | −$6.84M | −16.8%341.2K after | 2 lots10b5-1 |
| Sep 22, 2026 (view filing)5:04 PM ET | Sep 21-22 | 1 day | Sahin UgurChief Executive Officer | SSale | −79.0K | $99.50 | −$7.86M | −16.1%410.2K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)4:41 PM ET | Sep 17-18 | 1 day | Sahin UgurChief Executive Officer | SSale | −64.0K | $97.49 | −$6.24M | −11.6%489.2K after | 2 lots10b5-1 |
| Sep 16, 2026 (view filing)4:46 PM ET | Sep 15-16 | 1 day | Sahin UgurChief Executive Officer | SSale | −49.0K | $96.37 | −$4.72M | −8.1%553.2K after | 2 lots10b5-1 |
| Sep 14, 2026 (view filing)4:50 PM ET | Sep 11-14 | 3 days | Sahin UgurChief Executive Officer | SSale | −86.0K | $98.13 | −$8.44M | −12.5%602.2K after | 2 lots10b5-1 |
| Sep 11, 2026 (view filing)5:18 PM ET | Sep 10 | 1 day | Sahin UgurChief Executive Officer | SSale | −20.5K | $96.31 | −$1.97M | −2.9%688.2K after | 10b5-1 |
| Sep 9, 2026 (view filing)5:29 PM ET | Sep 8-9 | 1 day | Sahin UgurChief Executive Officer | SSale | −73.0K | $98.50 | −$7.19M | −9.3%708.7K after | 2 lots10b5-1 |
| Sep 8, 2026 (view filing)4:10 PM ET | Sep 3-4 | 5 days | Sahin UgurChief Executive Officer | SSale | −76.5K | $103.12 | −$7.89M | −8.9%781.7K after | 2 lots10b5-1 |
| Apr 23, 2026 (view filing) | Apr 22 | 1 day | Poetting SierkChief Operating Officer | SSale | −50.0K | $110.56 | −$5.53M | −11.1%399.4K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in BioNTech SE at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 7,571,805 | $704.6M | 0.03% | +1,862,565+32.6% | Added |
| Primecap Management Co | 3,772,031 | $351.0M | 0.21% | −21,680−0.6% | Reduced |
| Dodge & Cox | 3,677,591 | $342.2M | 0.18% | +8000.0% | Added |
| Flossbach Von Storch AG | 2,226,138 | $207.1M | 0.94% | −1,454,177−39.5% | Reduced |
| T. Rowe Price Investment Management, Inc. | 2,065,456 | $192.2M | 0.13% | −3,790,617−64.7% | Reduced |
| BlackRock, Inc. | 1,854,966 | $172.6M | 0.00% | +196,813+11.9% | Added |
| Temasek Holdings (Private) Ltd | 1,506,027 | $140.1M | 0.38% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 1,319,517 | $122.8M | 0.06% | −332,272−20.1% | Reduced |
| Logos Global Management LP | 1,015,000 | $94.4M | 4.07% | +1,015,000 | New |
| GSK plc | 889,824 | $82.8M | 13.75% | 00.0% | Unchanged |